EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain

Victor L Cruz iD, Virginia Souza-Egipsy, María Gion, José Pérez-García, Javier Cortes, Javier Ramos, Juan F Vega iD

International Journal of Molecular Sciences · 27.07.2023 · 24 (15) · 12031

DOI: 10.3390/ijms241512031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.07.2023. Verfasst von Victor L Cruz und 6 weiteren Autor:innen. Beteiligte Einrichtung: BIOPHYM, Department of Macromolecular Physics, Instituto de Estructura de la Materia, IEM-CSIC, C/Serrano 113 bis, 28006 Madrid, Spain. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Spanish National Research Council, Fundación FERO and Fundación “Contigo contra el cancer de la mujer”, CSIC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The binding affinity of trastuzumab and pertuzumab to HER2 has been studied using both experimental and in silico methods. The experiments were conducted using the antibodies in their complete IgG form, as used in clinical therapy, and the extracellular domain of the HER2 protein in solution. This approach provides a precise, reproducible, and reliable view of the interaction between them in physicochemical conditions similar to those found in the tumoral environment. Dynamic light scattering and size exclusion chromatography coupled with tetra detection were utilized to characterize the protein complexes, measure their concentrations, and calculate the equilibrium-free binding energy, ΔGbind. In addition, PRODIGY, a QSAR-like model with excellent predictive ability, was employed to obtain in silico ΔGbind estimations. The results obtained indicate that pertuzumab exhibits a slightly higher binding affinity to HER2 than trastuzumab. The difference in binding affinity was explained based on the contribution of the different interfacial contact (IC) descriptors to the ΔGbind value estimated by the PRODIGY model. Furthermore, experiments revealed that the pertuzumab IgG antibody binds preferentially to two HER2 proteins, one per Fab fragment, while trastuzumab mainly forms a monovalent complex. This finding was interpreted based on a geometrical model that identified steric crowding in the trastuzumab–HER2 complex as compared with the pertuzumab–HER2 complex.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalErb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsTrastuzumab

Stichwörter der Autor:innen

HER2binding free energypertuzumabprodigysize exclusion chromatographytrastuzumab

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedErb-b2 Receptor Tyrosine KinasesTrastuzumabpertuzumab

Autor:innen und Institutionen

  • BIOPHYM, Department of Macromolecular Physics, Instituto de Estructura de la Materia, IEM-CSIC, C/Serrano 113 bis, 28006 Madrid, Spain.
  • University Hospital Ramon y Cajal, 28304 Madrid, Spain.
  • International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, 08017 Barcelona, Spain.
  • Medical Scientia Innovation Research (MedSIR), 08018 Barcelona, Spain.
  • Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, 28108 Madrid, Spain.

ORCID-Profile: Victor L Cruz, Juan F Vega

Förderung

  • Spanish National Research Council
  • Fundación FERO and Fundación “Contigo contra el cancer de la mujer”
  • CSIC

Zitieren

APA

Cruz, V. L., Souza-Egipsy, V., Gion, M., Pérez-García, J., Cortes, J., Ramos, J., & Vega, J. F. (2023). Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain. International Journal of Molecular Sciences, 24(15), 12031. https://doi.org/10.3390/ijms241512031

Vancouver

Cruz VL, Souza-Egipsy V, Gion M, Pérez-García J, Cortes J, Ramos J, et al. Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain. International Journal of Molecular Sciences. 2023;24(15):12031. doi:10.3390/ijms241512031

BibTeX
@article{Cruz2023,
  author = {Cruz, Victor L and Souza-Egipsy, Virginia and Gion, María and Pérez-García, José and Cortes, Javier and Ramos, Javier and Vega, Juan F},
  title = {Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {15},
  pages = {12031},
  doi = {10.3390/ijms241512031}
}
Kostenlos starten →